StockVS

Translational Development Acquisition Corp. (TDAC) Análisis de acciones

Servicios Financieros

Translational Development Acquisition Corp.

$10.64

+$0.00 (+0.00%)

Última actualización: 26 de mayo de 2026

Historial de Precios

Análisis

Descripción de la empresa

Translational Development Acquisition Corp. (TDAC) operates as a special purpose acquisition company with no significant current operations, as it is structured to seek a business combination through mergers, amalgamations, or asset acquisitions with one or more target businesses. The company functions within the Financial Services sector, specifically categorized under the industry of Shell Companies, a classification that reflects its status as an entity awaiting a merger rather than one engaged in traditional revenue-generating activities. Its market capitalization stands at $232.22M, while the company reports no annual revenue and has no recorded employee count, indicating a purely speculative valuation based on future potential rather than current operational scale. These financial dimensions suggest that the market capitalization represents a premium assigned to the prospect of a future business combination, as the absence of revenue and staff implies that the asset's value is entirely contingent on the success of an upcoming transaction rather than existing business performance.

Salud financiera

The company reports zero revenue and zero net income for the trailing twelve-month period, with EBITDA also listed as unavailable, a combination that reveals a cost structure entirely driven by transaction expenses rather than operational overhead or cost of goods sold. Free cash flow is recorded at $-254,185, a negative figure that indicates the company is consuming cash reserves to sustain administrative costs and search for a target, thereby limiting its financial flexibility for opportunistic investments prior to a merger. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, which mathematically indicates that the company generates no gross profit or operating profit, as it has not yet established a revenue stream to offset its expenses. The balance sheet shows a cash balance of $29,787 against total debt of $200,000, creating a scenario where liabilities exceed liquid assets, a position that is inherently leveraged and not conservative given the lack of equity backing to cover the debt. The Debt to Equity ratio is unavailable due to the capital structure, but the Current Ratio of 0.07 signals severe short-term liquidity constraints, meaning the company possesses only seven cents of liquid assets for every dollar of current liabilities it owes. Return on Assets stands at -0.3%, while Return on Equity is unavailable, metrics that collectively reveal that management has not been effective in generating returns on the capital deployed, as the negative ROA reflects the erosion of asset value by expenses exceeding the negligible income generated.

Evaluación de valoración

The Trailing P/E Ratio is 36.55, while the Forward P/E is unavailable, a disparity that implies earnings are currently being calculated based on a historical net income of $6.36M despite the lack of reported revenue, creating a valuation metric that does not fully align with the current operational reality of the shell company. The Price to Book ratio is listed as -7.54, a negative figure that indicates the market is pricing the company below its book value, suggesting a significant discount or a market perception of high risk associated with the company's financial position. Both the Price to Sales ratio and EV/EBITDA are unavailable due to the absence of sales figures and EBITDA data, which prevents the use of these alternative valuation metrics to assess the company's worth relative to its revenue or earnings power. The stock has traded between a 52-week high of $10.60 and a 52-week low of $10.08, meaning the current price sits near the bottom of this historical range, reflecting investor hesitation to bid up the shares absent a confirmed merger target. The Beta value is unavailable, which prevents an assessment of the stock's price volatility relative to the broader market, leaving the risk profile regarding systemic market movements undefined based on standard statistical measures.

Growth & Income

Revenue Growth Year-over-Year and Earnings Growth Year-over-Year are both unavailable, which precludes any analysis of whether earnings are growing faster or slower than revenue, as the company currently lacks a historical revenue base to measure growth trajectories against. The company does not pay a dividend, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that the firm reinvests all available earnings, however minimal, into the search for a business combination rather than distributing income to shareholders. This non-dividend profile is typical for shell companies in the early stages of their lifecycle, where capital is retained to fund transaction costs and due diligence rather than providing income to investors. Consequently, the overall growth and income profile is characterized by zero current income distribution and undefined future growth rates until a successful business combination is executed and operations commence.

Comparación con pares

Translational Development Acquisition Corp. (TDAC) opera en la industria de Empresas Fantasma. Así se compara con sus pares más cercanos por capitalización de mercado:

Empresa Ticker Cap. de Mercado Ratio P/E
Translational Development Acquisition Corp. TDAC $233.10M 38.0
Twenty One Capital, Inc. XXI $2.49B N/A
Churchill Capital Corp X CCCX $711.00M N/A
Drugs Made In America Acquisition II Corp. DMII $641.46M 77.5

El ratio P/E promedio de la industria Empresas Fantasma es 82.8x. Translational Development Acquisition Corp. cotiza a un P/E de 38.0.

Este análisis es generado por IA solo con fines informativos y no constituye asesoramiento financiero. Los datos pueden estar retrasados o ser inexactos. Siempre realice su propia investigación y consulte a un asesor financiero calificado antes de tomar decisiones de inversión.

Acerca de Translational Development Acquisition Corp.

Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.

La descripción de la empresa se muestra en inglés.

Visitar sitio web →

Estadísticas Clave

Capitalización
$233.10M
Ratio P/E
38.00
Máximo 52 Sem.
$10.69
Mínimo 52 Sem.
$10.19
Volumen Promedio
8.82K

Datos proporcionados por Yahoo Finance a través de yfinance. Actualizado diariamente.

Información de la Empresa

Bolsa
NASDAQ
País
United States